This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

BAY59-7939 Japanese in Atrial Fibrillation (2nd)

This study has been completed.
Information provided by (Responsible Party):
Bayer Identifier:
First received: September 7, 2009
Last updated: December 26, 2014
Last verified: December 2014
This study was a randomized, parallel group, open label trial using warfarin as comparator. Pharmacokinetics (PK) and pharmacodynamics (PD) were investigated only in BAY59-7939 groups (originally described in Japanese).

Condition Intervention Phase
Atrial Fibrillation Drug: Xarelto (Rivaroxaban, BAY59-7939) Drug: Warfarin Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: BAY 59-7939 (Factor Xa Inhibitor) Phase II Low Dose Study in Patients With Atrial Fibrillation

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • (Safety) Incidence of bleeding [ Time Frame: Throughout treatment and followup period ]
  • (PK/PD) BAY 59-7939 concentrations / Factor Xa activity, PT, PT-INR, PTT and HEPTEST [ Time Frame: Day 14 and Day 28 ]

Enrollment: 100
Study Start Date: September 2005
Study Completion Date: March 2006
Arms Assigned Interventions
Experimental: Arm 1 Drug: Xarelto (Rivaroxaban, BAY59-7939)
2.5mg bid
Experimental: Arm 2 Drug: Xarelto (Rivaroxaban, BAY59-7939)
5mg bid
Experimental: Arm 3 Drug: Xarelto (Rivaroxaban, BAY59-7939)
10mg bid
Active Comparator: Arm 4 Drug: Warfarin
Dose-adjusted warfarin based on target INR values


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Japanese subjects with non-valvular AF who met all of the following criteria:

    • Persistent or paroxysmal non-valvular AF with >/=2 episodes before enrollment, at least 1 of which had been verified by ECG recording within 4 weeks before randomization
    • Male subjects aged 20 years or older and postmenopausal female subjects
    • Subjects with at least one risk factor for thromboembolism or aged 60 years or older (Risk factor for thromboembolism: hypertension, diabetes mellitus, coronary artery disease, congestive heart failure).

Exclusion Criteria:

  • History or presence of stroke or transient ischemic attack.
  • History of intracerebral hemorrhage.
  • History or presence of bleeding at randomization; intraocular or gastrointestinal bleeding within the last 6 months prior to randomization.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00973323

Kurume, Fukuoka, Japan, 830-8577
Maebaru, Fukuoka, Japan, 819-1104
Kitahiroshima, Hokkaido, Japan, 061-1134
Kushiro, Hokkaido, Japan, 085-0831
Sapporo, Hokkaido, Japan, 064-0807
Nomi, Ishikawa, Japan, 923-1100
Yokohama, Kanagawa, Japan, 227-0046
Tokorozawa, Saitama, Japan, 359-1141
Fukui, Japan, 910-0005
Oita, Japan, 870-0192
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Bayer Identifier: NCT00973323     History of Changes
Other Study ID Numbers: 12024
Study First Received: September 7, 2009
Last Updated: December 26, 2014

Keywords provided by Bayer:
Non-valvular atrial fibrillation
Japanese Patients
Phase II

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Factor Xa Inhibitors
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on June 22, 2017